Literature DB >> 10419897

Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia.

O Legrand1, G Simonin, A Beauchamp-Nicoud, R Zittoun, J P Marie.   

Abstract

In adult acute myeloid leukemia (AML), the weight of the contribution of the combined activity of Pgp and MRP1 to drug resistance is not known. To address this question, we compared the activity of these proteins to the in vitro resistance to daunorubicin (DNR), etoposide, and cytosine arabinoside (Ara-C), using the calcein-AM uptake and the 3-[4, 5-di-methyl-thiazol-2, 5-diphenyl] tetrazolium bromide (MTT) assay in 80 adult AML patients. We found no correlation or only a weak correlation between the in vitro drug resistance to DNR and etoposide and MRP1 or Pgp expression or function when tested separately. However, a strong correlation was observed between the simultaneous activity of MRP1 and Pgp (quantified as the modulation of calcein-AM uptake by cyclosporin A and probenecid) and the LC50 of DNR (r =.77, P <.0001). This emphasized the role of these two proteins, not separately, but together in the resistance to DNR. In contrast, Mvp/LRP expression did not correlate with the LC50 of DNR. A high level of simultaneous activity of Pgp and MRP1 was predictive of a poor treatment outcome (for achievement of CR [P =.008], duration of relapse-free survival [RFS; P =.01], and duration of overall survival [OS; P =.02]). In addition, high LC50 of DNR and high LC50 of etoposide together were also predictive of a poor treatment outcome (for duration of RFS [P =.02] and duration of OS [P =.02]). The unfavorable cytogenetic category was more closely associated with the combined activity of both MRP1 and Pgp (P =.002) than with the activity of Pgp or MRP1 separately. This could explain the poor prognosis and the in vitro resistance to daunorubicin in this group of patients. These data suggest that treatment outcome may be improved when cellular DNR and etoposide resistance can be circumvented or modulated. Modulation of not only Pgp but also MRP1 could be essential to attain this aim in adult AML.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419897

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

Review 1.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

2.  ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients.

Authors:  Christophe Marzac; Edith Garrido; Ruoping Tang; Fanny Fava; Pierre Hirsch; Cinzia De Benedictis; Elise Corre; Simona Lapusan; Jean-Yves Lallemand; Jean-Pierre Marie; Eric Jacquet; Ollivier Legrand
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

Review 3.  Overcoming transporter-mediated multidrug resistance in cancer: failures and achievements of the last decades.

Authors:  Miglė Paškevičiūtė; Vilma Petrikaitė
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

4.  Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.

Authors:  David Becton; Gary V Dahl; Yaddanapudi Ravindranath; Myron N Chang; Fred G Behm; Susana C Raimondi; David R Head; Kimo C Stine; Norman J Lacayo; Branimir Ivan Sikic; Robert J Arceci; Howard Weinstein
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

Review 5.  Older adults with acute myeloid leukemia.

Authors:  Mikkael A Sekeres; Richard Stone
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

Review 6.  Patterns of Care and Survival for Elderly Acute Myeloid Leukemia-Challenges and Opportunities.

Authors:  Abhishek A Mangaonkar; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2017-08       Impact factor: 3.952

7.  Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia.

Authors:  Hee Jin Huh; Chan Jeoung Park; Seongsoo Jang; Eul Ju Seo; Hyun Sook Chi; Je Hwan Lee; Kyoo Hyung Lee; Jong Jin Seo; Hyung Nam Moon; Thad Ghim
Journal:  J Korean Med Sci       Date:  2006-04       Impact factor: 2.153

8.  Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models.

Authors:  Emma Morrish; Anthony Copeland; Donia M Moujalled; Jason A Powell; Natasha Silke; Ann Lin; Kate E Jarman; Jarrod J Sandow; Gregor Ebert; Liana Mackiewicz; Jessica A Beach; Elizabeth L Christie; Alexander C Lewis; Giovanna Pomilio; Karla C Fischer; Laura MacPherson; David D L Bowtell; Andrew I Webb; Marc Pellegrini; Mark A Dawson; Stuart M Pitson; Andrew H Wei; John Silke; Gabriela Brumatti
Journal:  Blood Adv       Date:  2020-10-27

9.  Isocyclopamine, a novel synthetic derivative of cyclopamine, reverts doxorubicin resistance in MCF-7/ADR cells by increasing intracellular doxorubicin accumulation and downregulating breast cancer stem-like cells.

Authors:  Ming Liu; Weiyi Zhang; Wei Tang; Yanjuan Wang; Xingzeng Zhao; Xiangyun Wang; Xin Qi; Jing Li
Journal:  Tumour Biol       Date:  2015-09-02

10.  Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).

Authors:  Robert W Robey; Suneet Shukla; Elizabeth M Finley; Robert K Oldham; Daryl Barnett; Suresh V Ambudkar; Tito Fojo; Susan E Bates
Journal:  Biochem Pharmacol       Date:  2007-12-14       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.